BU-NOT-SET

CONTACT US
Recipharm’s global teams support and engage with their local communities in the fight against COVID-19
  • Corporate
Eyes
Insight
Recipharm launches new virtual inspection and audit tool for customers, in light of COVID-19 outbreak
  • Manufacturing
Eyes
Insight
Recipharm 25 years
  • Corporate
24 years
Brochure
API product list
  • Drug substance
white pills
Fact sheet
Inhibition of 19S proteasome deubiquitinating activity in Schistosoma mansoni affects viability, oviposition, and structural changes
  • Drug substance
Eyes
Insight
The demand for antibiotics and its impact on the pharmaceutical industry since the outbreak of COVID-19
  • Industry trends
Eyes
Insight
Women in leadership
  • Corporate
Eyes
Insight
The state of the oral solid dose development and manufacturing market
  • Drug product
Eyes
Insight
Characterising APIs is Essential for Combo Drug Formulations
  • Drug substance
Eyes
Insight
Insight
  • Biologics
Innovation & leadership across the advanced therapy space
Insight
  • Biologics
Overcoming oncolytic virus obstacles with the help of a CDMO partnership
Webinar
  • Biologics
Webinar: Beyond borders: Navigating global scale-up for viral-based therapies
eBook
  • Drug product
Choosing the right container for your sterile drug product
White paper
  • Biologics
Cell and virus banking in OV development and manufacturing
Insight
  • Biologics
Overcoming technical transfer challenges in virotherapy manufacturing
eBook
  • Biologics
Flexibility in gene therapy: Adapting to the unique gene therapy demands
Webinar
  • Biologics
Webinar: An optimised Plasmid DNA platform
Insight
  • Drug substance
  • Industry trends
The future of oral solid dose formulations